Skip to main content
Springer Nature Link
Log in

Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Platinum-based therapy is the cornerstone of ovarian cancer treatment. Development of platinum hypersensitivity can limit therapeutic options. In this brief report, we present case of successful cisplatin administration following two unsuccessful carboplatin desensitization attempts, and without the need for pre-treatment steroids.

Methods

Retrospective chart review was performed.

Results

One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin-based regimen, developed a platinum hypersensitivity. Two attempts at carboplatin desensitization were unsuccessful. Cisplatin was substituted and the patient achieved a complete response to therapy without further hypersensitivity.

Conclusions

Platinum-based therapies are vital to the treatment of primary peritoneal and ovarian carcinoma. Protocols that successfully incorporate platinum agents, despite a platinum hypersensitivity, are clinically relevant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin–DNA adducts. Chem Rev 99(9):2467–2498

    Article  CAS  PubMed  Google Scholar 

  2. Everett EN, French AE, Stone RL, Pastore LM, Jazaeri AA, Andersen WA et al (2006) Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol 195(2):568–574 (discussion 574–576)

    Article  PubMed  Google Scholar 

  3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43

    Article  CAS  PubMed  Google Scholar 

  4. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194–3200

    Article  CAS  PubMed  Google Scholar 

  5. Sliesoraitis S, Chikhale PJ (2005) Carboplatin hypersensitivity. Int. J. Gynecol. Cancer 15(1):13–18

    Article  CAS  PubMed  Google Scholar 

  6. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ et al (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9(7):1138–1150

    CAS  PubMed  Google Scholar 

  7. Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR (2002) Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 84(3):378–382

    Article  CAS  PubMed  Google Scholar 

  8. Rose PG, Fusco N, Smrekar M, Mossbruger K, Rodriguez M (2003) Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 89(3):429–433

    Article  CAS  PubMed  Google Scholar 

  9. Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK (2001) Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 82(3):550–558

    Article  CAS  PubMed  Google Scholar 

  10. McGuire WP, Ozols RF (1998) Chemotherapy of advanced ovarian cancer. Semin Oncol 25(3):340–348

    CAS  PubMed  Google Scholar 

  11. Callahan MB, Lachance JA, Stone RL, Kelsey J, Rice LW, Jazaeri AA (2007) Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol 197(2):199e.1–199e.14 (discussion 199.e4–e5)

    Article  Google Scholar 

  12. Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J (2004) Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res 64(1):356–362

    Article  CAS  PubMed  Google Scholar 

  13. Zweizig S, Roman LD, Muderspach LI (1994) Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 53(1):121–122

    Article  CAS  PubMed  Google Scholar 

  14. Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J (2003) Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 21(24):4611–4614

    Article  CAS  PubMed  Google Scholar 

  15. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV et al (2009) Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 123(6):1262–1267

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

All authors indicate there are no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. University of Virginia School of Medicine, Charlottesville, VA, USA

    Daniel P. Greene

  2. Thornton Gynecologic Oncology Service, Department of Obstetrics and Gynecology, University of Virginia Health System, P.O. Box 800712, Charlottesville, VA, 22908, USA

    James Stuart Ferriss & Amir A. Jazaeri

Authors
  1. Daniel P. Greene
    View author publications

    Search author on:PubMed Google Scholar

  2. James Stuart Ferriss
    View author publications

    Search author on:PubMed Google Scholar

  3. Amir A. Jazaeri
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to James Stuart Ferriss.

Additional information

D. P. Greene and J. S. Ferriss contributed equally to the research and final manuscript preparation.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Greene, D.P., Ferriss, J.S. & Jazaeri, A.A. Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report. Cancer Chemother Pharmacol 66, 265–267 (2010). https://doi.org/10.1007/s00280-009-1159-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-009-1159-6

Keywords